Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • TA127
  • Published: 
  • Last updated: 
Download guidance (PDF)

8 Sources of evidence considered by the committee

The evidence review group (ERG) report for this appraisal was prepared by Peninsula Technology Assessment Group, University of Exeter:

  • Ruth Garside, Colin Green, Martin Hoyle, et al. (2007) The effectiveness and cost effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen.

The following company or sponsor provided a submission for this appraisal:

  • Biogen Idec UK and Elan Pharma International

The following organisations accepted the invitation to participate in this appraisal. They are also invited to comment on the appraisal consultation document and supporting evidence. Consultee organisations have the opportunity to appeal against the final appraisal determination.

Professional or specialist, patient or carer groups, and other organisations:

  • Association of British Neurologists

  • Multiple Sclerosis Society

  • Multiple Sclerosis Trust

  • Primary Care Neurology Society

  • Royal College of Nursing

  • Royal College of Physicians

  • UK Multiple Sclerosis Specialist Nurse Association

  • Department of Health

  • Oldham PCT

  • Welsh Assembly Government

Commentator organisations (without the right of appeal):

  • Amgen (mitoxantrone)

  • Biogen Idec UK (interferon beta-1a)

  • British National Formulary

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Medicines and Healthcare products Regulatory Agency (MHRA)

  • Multiple Sclerosis Group, University of Bristol

  • National Coordinating Centre for Health Technology Assessment

  • National Collaborating Centre for Chronic Conditions

  • NHS Quality Improvement Scotland

  • Peninsula Technology Assessment Group, University of Exeter

  • Schering Health Care (interferon beta-1b)

  • Serono (interferon beta-1a)

  • Teva Pharmaceuticals (glatiramer acetate).

The following individuals were selected from clinical specialist and patient advocate nominations from the professional or specialist, and patient or carer groups. They gave their expert personal view on natalizumab for the treatment of multiple sclerosis by providing written evidence to the committee. They are invited to comment on the appraisal consultation document:

  • Professor David Miller, nominated as a clinical expert by the Association of British Neurologists.

  • Professor Alan Thompson, nominated as a clinical expert by the Multiple Sclerosis Society.

  • Megan Burgess, nominated as a clinical expert by the Royal College of Nursing.

  • Mrs Caroline Haynes, nominated as a patient expert by the
    MS Trust.

  • Mr Mark Priest, nominated as a patient expert by the MS Trust.